Pediatric patient with severe psoriasis surprised by successful response to monoclonal treatment

There was no recurrence after 16 weeks of follow-up.

The 9-year-old girl revealed extensive erythematous plaques with thick scales covering more than 80% of her body. Photo: Wiley Pediatric Dermatology.

patient A pediatric patient from Puerto Rico surprised doctors because of the manifestations caused by severe plaque psoriasis, which was refractory to many local and systemic therapies.

The 9-year-old girl revealed extensive erythematous plaques with thick scales covering more than 80% of the surface of her body, including the face, scalp, body and limbs.

Doctors attached to the medical campus decided to treat her with etanercept, the only biological option approved by the FDA for this type of psoriasis, but after 9 months her clinical response was minimal.

But then the team decided to start this patient ustekinumab therapy following the instructions for adults weighing less than 100 kg.

Three weeks after starting treatment, her psoriatic lesions had almost completely disappeared. There was also no recurrence after 16 weeks of follow-up, no abnormalities in her laboratory results, and no serious complications, except for one urinary tract infection uncomplicated, which is resolved with oral antibiotics.

It should be noted that the use of ustekinumab is part of the study. “A multicenter, randomized, double-blind, placebo-controlled phase 3 study evaluating the efficacy and safety of this treatment in adolescents with psoriasis in moderate to severe plaque “, and it is the data that support the researchers’ proposal to establish a safe and effective biological therapy for children aged 12-17 years.

However, the patient treated in Puerto Rico is 9 years old and no studies have been conducted to evaluate the effectiveness of the treatment. drugs in younger pediatric patients of 12 years, although this case may indicate that treatment may have potential in patients of this age.

Access the case here.